Approval · Notice of Compliance 779 · 2002
RATIO-RANITIDINE: Notice of Compliance 779
Issued August 27, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 779
- Date
- August 27, 2002
- Company
- Ratiopharm Inc.Ulm, --, Germany
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Histamine h2-receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RATIO-RANITIDINE | 00828823 | Cancelled Post Market |
| RATIO-RANITIDINE | 00828688 | Cancelled Post Market |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB